Bristol Myers Squibb (BMY 2.15%) is a leading biopharmaceutical company focused on innovative medicines in oncology, cardiovascular, immunology, and neuroscience. On July 31, 2025, it released results for the second quarter, reporting GAAP revenue and non-GAAP EPS that exceeded Wall Street expectations. The company achieved GAAP revenue of $12.269 billion, compared to an analyst estimate of $11.385 billion, and non-GAAP earnings per share (EPS) of $1.46, surpassing the estimated $1.07 per share. Despite the ...